Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma.
Loading...
Embargo End Date
ICR Authors
Authors
Chrisochoidou, Y
Scarpino, A
Morales, S
Martin, S
Bird, S
Li, Y
Walker, B
Caldwell, J
Le Bihan, Y-V
Pawlyn, C
Scarpino, A
Morales, S
Martin, S
Bird, S
Li, Y
Walker, B
Caldwell, J
Le Bihan, Y-V
Pawlyn, C
Document Type
Journal Article
Date
2025-05-29
Date Accepted
2024-12-19
Abstract
Immunomodulatory drug (IMiD) resistance is a key clinical challenge in myeloma treatment. Previous data suggest almost one-third of myeloma patients acquire genetic alteration of the key IMiD effector cereblon (CRBN) by the time they are pomalidomide refractory. Some events, including stop codons/frameshift mutations and copy loss, have clearly explicable effects on CRBN protein function. Missense mutations have also been reported throughout the length of CRBN but their functional impact has not been systematically studied. This study modeled selected missense mutations and examined their effect on CRBN function also analyzing whether any mutations deleterious to IMiD action could be overcome using the novel cereblon E3 ligase modulators (CELMoDs). Three patterns of response to missense mutations were apparent: mutations that led to complete loss of CRBN function for all agents, those that had no effect on CRBN function, and those with agent-dependent effect on CRBN function. The latter group of 4 mutations were profiled in more detail with confirmatory experiments demonstrating an ability of the more potent CELMoDs to lead to neosubstrate degradation and cell death even though IMiDs were not active. Dynamic modeling based on a newly generated crystal structure of the DDB1/CRBN/lenalidomide complex, with greater resolution than those published to date, helped to understand the impact of these mutations. These results have important implications for the interpretation of CRBN sequencing results from patients for future therapy decisions, particularly differentiating those who may, despite relapsing on IMiDs with CRBN mutations, have the potential to still benefit from the use of CELMoD agents.
Citation
Blood, 2025, 145 (22), pp. 2630 - 2644
Source Title
Blood
Publisher
ELSEVIER
ISSN
0006-4971
eISSN
1528-0020
Collections
Research Team
Targeted Protein Degrad
Myeloma Biol Therap
Myeloma Biol Therap